Trademark: 97164184
Word
LLDX
Status
Pending
Status Code
688
Status Date
Tuesday, October 31, 2023
Serial Number
97164184
Mark Type
4000
Filing Date
Thursday, December 9, 2021
Published for Opposition
Tuesday, September 5, 2023

Trademark Owner History
LeukoLifeDx, Inc. - Owner At Publication

Classifications
5 Gene therapy products, namely, living and genetically engineered tissues for use in predictive and diagnostic medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays for testing and predicting patient recovery; medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic test kits for medical use comprising reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical diagnostic test kits for detecting pathogens, comprising reagents for medical use; medical diagnostic reagents for RNA transcription and microRNA expression profiling, proteomics, small molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphisms in human fluids, detection of copy number variations, and clinical, oncology, and hematology diagnostics; medical diagnostic reagents and diagnostic reagents for clinical or medical laboratory use, diagnostic reagents for medical in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use; medical diagnostic reagents and assays for testing of body fluids; kits consisting primarily of medical diagnostic reagents and assays for testing of body fluids; reagents in the form of cell markers and molecule markers for medical purposes
1 Assays and reagents for research purposes; diagnostic preparations for scientific use; diagnostic reagents for scientific research relating to molecular identification and digital quantification; chemical test kits for scientific research use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation therefor; chemical test kits comprising reagents for scientific research relating to molecular identification; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for clinical or medical laboratory use, namely, reagents for proteomics, RNA transcription, and microRNA expression profiling, small-molecule analysis, single nucleotide polymorphisms analysis, DNA sequencing, detection of polymorphisms in human fluids, detection of copy number variations, and clinical, oncology, and hematology diagnostics; reagents for scientific or medical research use, diagnostic preparations and reagents for scientific or research uses, namely, RNA transcription profiling, proteomics, clinical diagnostics of samples containing microorganisms or human fluids, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing; test kits consisting of chemical preparations for scientific research purposes for the detection, diagnosis, progress monitoring and progress prediction of diseases, namely inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers; assays, reagents, enzymes, polymerases, buffers and nucleotides, and kits comprised thereof, all for scientific or research use; diagnostic reagents for scientific in vitro use in biochemistry, clinical chemistry and microbiology, RNA and microRNA expression transcription profiling, proteomics, clinical diagnostics, small-molecule analysis, single nucleotide polymorphisms analysis, and DNA sequencing
44 Medical diagnostic testing, monitoring and reporting services; genetic medical testing service; providing medical information to patients and medical professionals in the form of reports in a wide variety of medical fields; medical services; providing medical information relating to the diagnostic, prophylactic, and therapeutic properties of assays and reagents; providing medical record analysis services designed to provide patients and medical professionals with custom tailored information about the range of possible diagnoses and therapies
10 Diagnostic test kits for use in microbial testing comprising reagents, slides, solid matrix materials, microfluidic devices, and support documentation therefor
42 Custom design and development of chemical reagents and biochemical assays; research and product development services for others in the field of biotechnology; providing laboratory research services in the field of gene expression; genetic data mining; development of molecule identification methods for acquiring, analyzing, and managing biological and genetic information, in the fields of genetics research and development services for others in the fields of diagnostic compounds for use in medicine, measuring apparatus for use in product research and development, laboratory separation and purification processes, laboratory testing processes, and industrial quality control processes; developing systems for acquiring, analyzing, and managing biological and genetic information in the fields of diagnostic reagents, forensics, medicine, and genetics; research, design, and development services for others in the fields of diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, laboratory separation and purification processes, laboratory testing processes, and industrial quality control processes; chemical screening analysis for others
LEUKO LIFE DX

Trademark Events
Oct 31, 2023
Noa E-Mailed - Sou Required From Applicant
Sep 5, 2023
Official Gazette Publication Confirmation E-Mailed
Sep 5, 2023
Published For Opposition
Aug 16, 2023
Notification Of Notice Of Publication E-Mailed
Jul 28, 2023
Approved For Pub - Principal Register
Jul 27, 2023
Assigned To Examiner
Jul 27, 2023
Teas/Email Correspondence Entered
Jul 27, 2023
Correspondence Received In Law Office
Jul 27, 2023
Teas Response To Office Action Received
Apr 29, 2023
Notification Of Non-Final Action E-Mailed
Apr 29, 2023
Non-Final Action E-Mailed
Apr 29, 2023
Non-Final Action Written
Mar 20, 2023
Teas/Email Correspondence Entered
Mar 17, 2023
Correspondence Received In Law Office
Mar 17, 2023
Teas Response To Office Action Received
Sep 19, 2022
Notification Of Non-Final Action E-Mailed
Sep 19, 2022
Non-Final Action E-Mailed
Sep 19, 2022
Non-Final Action Written
Sep 17, 2022
Assigned To Examiner
Dec 14, 2021
New Application Office Supplied Data Entered
Dec 13, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24